Phenotypic diversity of breast cancer-related mutations in metalloproteinase-disintegrin ADAM12

PLoS ONE

Volumn 9, Issue 3, 2014, Pages

  Qi, Yue ^a   Duhachek Muggy, Sara ^a   Lino, Hui ^a   Zolkiewska, Anna ^a  

^a KANSAS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM12 PROTEIN; UNCLASSIFIED DRUG;

ADAM12 GENE; AMINO TERMINAL SEQUENCE; ARTICLE; BREAST CANCER; CATALYSIS; CELL SURFACE; CONTROLLED STUDY; ENDOPLASMIC RETICULUM; GENE; GENE MUTATION; HUMAN; HUMAN CELL; LOSS OF FUNCTION MUTATION; MISSENSE MUTATION; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN TRANSPORT; TRIPLE NEGATIVE BREAST CANCER;

ADAM PROTEINS; ALLELES; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; BREAST NEOPLASMS; CATALYSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENETIC ASSOCIATION STUDIES; HUMANS; INTRACELLULAR SPACE; MEMBRANE PROTEINS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MUTATION; PHENOTYPE; PROTEIN CONFORMATION; PROTEIN TRANSPORT; PROTEOLYSIS; SEQUENCE ALIGNMENT; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84908417802     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0092536     Document Type: Article

References (37)

1. Edwards DR, Handsley MM, Pennington CJ (2008) The ADAM metalloproteinases. Mol Aspects Med 29: 258-289.
2. Weber S, Saftig P (2012) Ectodomain shedding and ADAMs in development. Development 139: 3693-3709.
3. Iba K, Albrechtsen R, Gilpin BJ, Loechel F, Wewer UM (1999) Cysteine-rich domain of human ADAM 12 (meltrin a) supports tumor cell adhesion. Am J Pathol 154: 1489-1501. (Pubitemid 29226444)
4. Kveiborg M, Frohlich C, Albrechtsen R, Tischler V, Dietrich N, et al. (2005) A role for ADAM12 in breast tumor progression and stromal cell apoptosis. Cancer Res 65: 4754-4761. (Pubitemid 40740812)
5. Lendeckel U, Kohl J, Arndt M, Carl-McGrath S, Donat H, et al. (2005) Increased expression of ADAM family members in human breast cancer and breast cancer cell lines. J Cancer Res Clin Oncol 131: 41-48.
6. Mitsui Y, Mochizuki S, Kodama T, Shimoda M, Ohtsuka T, et al. (2006) ADAM28 is overexpressed in human breast carcinomas: implications for carcinoma cell proliferation through cleavage of insulin-like growth factor binding protein-3. Cancer Res 66: 9913-9920. (Pubitemid 44672043)
7. Bertucci F, Finetti P, Cervera N, Charafe-Jauffret E, Mamessier E, et al. (2006) Gene expression profiling shows medullary breast cancer is a subgroup of basal breast cancers. Cancer Res 66: 4636-4644.
8. Turashvili G, Bouchal J, Baumforth K, Wei W, Dziechciarkova M, et al. (2007) Novel markers for differentiation of lobular and ductal invasive breast carcinomas by laser microdissection and microarray analysis. BMC Cancer 7: 55.
9. Roy R, Moses MA (2011) ADAM12 induces estrogen-independence in breast cancer cells. Breast Cancer Res Treat 131: 731-741.
10. Li H, Duhachek-Muggy S, Qi Y, Hong Y, Behbod F, et al. (2012) An essential role of metalloprotease-disintegrin ADAM12 in triple-negative breast cancer. Breast Cancer Res Treat 135: 759-769.
11. Kveiborg M, Albrechtsen R, Couchman JR, Wewer UM (2008) Cellular roles of ADAM12 in health and disease. Int J Biochem Cell Biol 40: 1685-1702.
12. Dillon LW, Pierce LC, Ng MC, Wang YH (2013) Role of DNA secondary structures in fragile site breakage along human chromosome 10. Hum Mol Gen 22: 1443-1456.
13. Sjoblom T, Jones S, Wood LD, Parsons DW, Lin J, et al. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314: 268-274. (Pubitemid 44571966)
14. Shah SP, Roth A, Goya R, Oloumi A, Ha G, et al. (2012) The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 486: 395-399.
15. Jiao X, Wood LD, Lindman M, Jones S, Buckhaults P, et al. (2012) Somatic mutations in the Notch, NF-kB, PIK3CA, and Hedgehog pathways in human breast cancers. Genes, Chromosomes & Cancer 51: 480-489.
16. Dyczynska E, Syta E, Sun D, Zolkiewska A (2008) Breast cancer-associated mutations in metalloprotease disintegrin ADAM12 interfere with the intracellular trafficking and processing of the protein. Int J Cancer 122: 2634-2640. (Pubitemid 351590502)
17. Stautz D, Wewer UM, Kveiborg M (2012) Functional analysis of a breast cancer-associated mutation in the intracellular domain of the metalloprotease ADAM12. PLoS One 7: e37628.
18. Dyczynska E, Sun D, Yi H, Sehara-Fujisawa A, Blobel CP, et al. (2007) Proteolytic processing of Delta-like 1 by ADAM proteases. J Biol Chem 282: 436-444. (Pubitemid 47076599)
19. Li H, Duhachek-Muggy S, Dubnicka S, Zolkiewska A (2013) Metalloproteinase-disintegrin ADAM12 is associated with a breast tumor-initiating cell phenotype. Breast Cancer Res Treat 139: 691-703.
20. Roy A, Kucukural A, Zhang Y (2010) I-TASSER: a unified platform for automated protein structure and function prediction. Nature Protocols 5: 725-738.
21. Zhang Y (2008) I-TASSER server for protein 3D structure prediction. BMC Bioinformatics 9: 40.
22. Liu H, Shim AH, He X (2009) Structural characterization of the ectodomain of a disintegrin and metalloproteinase-22 (ADAM22), a neural adhesion receptor instead of metalloproteinase: insights on ADAM function. J Biol Chem 284: 29077-29086.
23. Horiuchi K, Le Gall S, Schulte M, Yamaguchi T, Reiss K, et al. (2007) Substrate selectivity of epidermal growth factor-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol Biol Cell 18: 176-188. (Pubitemid 46066719)
24. Frohlich C, Klitgaard M, Noer JB, Kotzsch A, Nehammer C, et al. (2013) ADAM12 is expressed in the tumour vasculature and mediates ectodomain shedding of several membrane-anchored endothelial proteins. Biochem J 452: 97-109.
25. Asakura M, Kitakaze M, Takashima S, Liao Y, Ishikura F, et al. (2002) Cardiac hypertrophy is inhibited by antagonism of ADAM12 processing of HB-EGF: metalloproteinase inhibitors as a new therapy. Nat Med 8: 35-40. (Pubitemid 34101726)
26. Diaz B, Yuen A, Iizuka S, Higashiyama S, Courtneidge SA (2013) Notch increases the shedding of HB-EGF by ADAM12 to potentiate invadopodia formation in hypoxia. J Cell Biol 201: 279-292.
27. Olayioye MA, Neve RM, Lane HA, Hynes NE (2000) The ErbB signaling network: receptor heterodimerization in development and cancer. EMBO J 19: 3159-3167. (Pubitemid 30428195)
28. Rao VH, Kandel A, Lynch D, Pena Z, Marwaha N, et al. (2012) A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion. Oncogene 31: 2888-2898.
29. Roy R, Rodig S, Bielenberg D, Zurakowski D, Moses MA (2011) ADAM12 transmembrane and secreted isoforms promote breast tumor growth: a distinct role for ADAM12-S protein in tumor metastasis. J Biol Chem 286: 20758-20768.
30. Harsha A, Stojadinovic O, Brem H, Sehara-Fujisawa A, Wewer U, et al. (2008) ADAM12: a potential target for the treatment of chronic wounds. J Mol Med 86: 961-969.
31. Huang J, Bridges LC, White JM (2005) Selective modulation of integrin mediated cell migration by distinct ADAM family members. Mol Biol Cell 16: 4982-4991. (Pubitemid 41416475)
32. Kumar P, Henikoff S, Ng PC (2009) Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm. Nature Protocols 4: 1073-1081.
33. Adzhubei IA, Schmidt S, Peshkin L, Ramensky VE, Gerasimova A, et al. (2010) A method and server for predicting damaging missense mutations. Nature Methods 7: 248-249.
34. The Cancer Genome Atlas Network (2012) Comprehensive molecular portraits of human breast tumours. Nature 490: 61-70.
35. Beroukhim R, Mermel CH, Porter D, Wei G, Raychaudhuri S, et al. (2010) The landscape of somatic copy-number alteration across human cancers. Nature 463: 899-905.
36. Creighton CJ (2012) The molecular profile of luminal B breast cancer. Biologics: Targets & Therapy 6: 289-297.
37. Tran B, Bedard PL (2011) Luminal-B breast cancer and novel therapeutic targets. Breast Cancer Res 13: 221.